Acusphere Receives Complete Response from FDA (Business Wire via Yahoo! Finance)
TEWKSBURY, Mass.----Acusphere, Inc. announced today that it has received a complete response from the U.S. Food & Drug Administration . The response was largely consistent with the feedback received at the Advisory Committee meeting on December 10, 2008, and discussions that continued with FDA in January 2009.

FDA Approves An Expanded Indication For Peginterferon-Based Combination Therapy For Patients With Chronic Hepatitis C (Medical News Today)
Schering-Plough Corporation (NYSE: SGP) announced that the U.S. Food and Drug Administration (FDA) has approved new labeling for PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy for treating chronic hepatitis C in patients 3 years of age and older with compensated liver disease.